Anelixis announces the conclusion of AT-1501 Phase 1 clinical trial
Category: #health  By Saipriya Iyer  Date: 2019-11-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Anelixis announces the conclusion of AT-1501 Phase 1 clinical trial

Anelixis Therapeutics has reportedly concluded its testing of an investigational antibody, AT-1501, in a Phase 1 clinical trial in healthy volunteers as well as eight patients suffering from amyotrophic lateral sclerosis (ALS). The company further announced that it has raised enough funds to advance to AT-1501’s Phase 2 clinical trial.

The Phase 1 trial came out with a positive result as AT-1501 was well-tolerated at every dose that was tested. The processing of the drug inside the body, which is also called pharmacokinetics, was the same as was predicted by the researchers. The details of the study are to be presented at scientific meetings expected held in the future.

The company anticipates this data to support more clinical studies regarding ALS as well as other disorders to further analyze the tolerability and safety of AT-1501, including other clinical parameters like potential biomarkers.

AT-1501 happens to be an investigational antibody targeting CD40 ligand (CD40L), which is essentially a kind of protein on the surface of white blood cells causing inflammation. The U.S. Food and Drug Administration has given this therapy the designation of an orphan drug. 

The ALS Therapy Development Institute (ALS TDI) has developed AT-1501 with the help of numerous ALS organizations such as ALS Finding a Cure, ALS Association and ALS ONE. The Phase 1 trial was funded by ALS Association by over $1 million.

CEO and Founder of Anelixis, Steven Perrin, Ph.D., stated that allograft rejection, autoimmune diseases and ALS represent large unmet medical needs and the company is looking forward to exploring AT-1501’s potential value as diligently and quickly as possible. Advancement of the drug into a strong clinical research program will be providing significant potential opportunities for all the patients both in the ALS and the diabetes communities, he added.

 

Source Credits- https://alsnewstoday.com/2019/11/21/anelixis-therapeutics-als-therapy-at-1501-phase-2-clinical-trial/



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...